Related Experiment Video

Updated: Jun 25, 2026

Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

Experience with pneumococcal conjugate vaccine in Norway

Ingeborg S Aaberge1

  • 1Department Director, Department of Bacteriology & Immunology, Division of Infectious Disease Control, Norwegian Institute of Public Health, PO Box 4404, Nydalen, NO-0403 Oslo, Norway. ingeborg.aaberge@fhi.no

Expert Review of Vaccines
|February 7, 2009
PubMed

Insights

The seven-valent pneumococcal conjugate vaccine (PCV7) program in Norway significantly reduced invasive pneumococcal disease in young children. The vaccine achieved 74% effectiveness, demonstrating its public health impact.

Area of Science:

  • Pediatrics
  • Immunology
  • Public Health

Background:

  • Invasive pneumococcal disease (IPD) poses a significant threat to young children.
  • The introduction of pneumococcal conjugate vaccines aims to reduce the burden of IPD.

Purpose of the Study:

  • To evaluate the effectiveness of the seven-valent pneumococcal conjugate vaccine (PCV7) in the Norwegian childhood vaccination program.
  • To assess the impact of PCV7 on the incidence of IPD in children under two years of age.

Main Methods:

  • The study likely involved analyzing IPD incidence data before and after PCV7 introduction.
  • Vaccine coverage rates were monitored to assess program uptake.

Main Results:

  • PCV7 was introduced in July 2006 on a 2+1 dose schedule.
  • High vaccine coverage was rapidly achieved following introduction.
  • A rapid decline in IPD incidence was observed in children under two years.
  • The estimated vaccine program effectiveness was 74%.

Conclusions:

  • The seven-valent pneumococcal conjugate vaccine program in Norway has been highly effective.
  • PCV7 significantly reduced the incidence of invasive pneumococcal disease in young children.
  • The findings support the continued use and importance of pneumococcal conjugate vaccination.

More Related Videos

Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens08:47

Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens

Published on: April 5, 2019

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/4306:06

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43

Published on: September 11, 2020

Related Concept Videos

Streptococcal Pharyngitis01:27

Streptococcal Pharyngitis

Streptococcal pharyngitis, commonly known as “strep throat,” is an acute infection of the oropharyngeal tissues caused by the Gram‑positive Group A Streptococcus (Streptococcus pyogenes). Transmission occurs primarily through respiratory droplets expelled during coughing, sneezing, or talking.Mechanisms of Host Entry and Immune EvasionUpon entering the host, S. pyogenes adheres to the mucosal epithelial cells of the pharynx via surface proteins, notably lipoteichoic acid and the antiphagocytic...
Vaccinations01:51

Vaccinations

Overview
Vaccines01:21

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...